相似文献
1
A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Drug Discov Today. 2018 Jul;23(7):1344-1356. doi: 10.1016/j.drudis.2018.03.003. Epub 2018 Mar 15.
2
[Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies].
Mol Biol (Mosk). 2017 Nov-Dec;51(6):907-926. doi: 10.7868/S0026898417060040.
3
Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.
JAMA Oncol. 2024 May 1;10(5):563-564. doi: 10.1001/jamaoncol.2024.0008.
4
Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.
Curr Opin Chem Biol. 2015 Oct;28:29-38. doi: 10.1016/j.cbpa.2015.05.021. Epub 2015 Jun 5.
5
Theranostic barcoded nanoparticles for personalized cancer medicine.
Nat Commun. 2016 Nov 10;7:13325. doi: 10.1038/ncomms13325.
6
Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Drug Discov Today. 2020 Jul;25(7):1245-1252. doi: 10.1016/j.drudis.2020.04.018. Epub 2020 May 1.
7
Fate of Antibody-Drug Conjugates in Cancer Cells.
J Exp Clin Cancer Res. 2018 Feb 6;37(1):20. doi: 10.1186/s13046-017-0667-1.
8
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Eur J Med Chem. 2017 Dec 15;142:393-415. doi: 10.1016/j.ejmech.2017.08.049. Epub 2017 Aug 23.
9
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
Target Oncol. 2019 Dec;14(6):631-637. doi: 10.1007/s11523-019-00678-w.
10
Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
Clin Pharmacol Ther. 2020 Sep;108(3):515-527. doi: 10.1002/cpt.1942. Epub 2020 Aug 6.
引用本文的文献
1
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.
Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640.
2
Radiomics characterization of tissues in an animal brain tumor model imaged using dynamic contrast enhanced (DCE) MRI.
Sci Rep. 2023 Jul 2;13(1):10693. doi: 10.1038/s41598-023-37723-8.
3
Advanced Optical Imaging-Guided Nanotheranostics towards Personalized Cancer Drug Delivery.
Nanomaterials (Basel). 2022 Jan 26;12(3):399. doi: 10.3390/nano12030399.
4
ADAM17 Mediates Hypoxia-Induced Keratinocyte Migration via the p38/MAPK Pathway.
Biomed Res Int. 2021 Oct 28;2021:8328216. doi: 10.1155/2021/8328216. eCollection 2021.
5
Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine.
Cancers (Basel). 2020 Sep 29;12(10):2793. doi: 10.3390/cancers12102793.
6
Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.
Drug Discov Today. 2020 Apr;25(4):718-730. doi: 10.1016/j.drudis.2019.11.006. Epub 2019 Nov 20.
7
Fabrication of Ion-Crosslinking Aminochitosan Nanoparticles for Encapsulation and Slow Release of Curcumin.
Pharmaceutics. 2019 Nov 7;11(11):584. doi: 10.3390/pharmaceutics11110584.
8
Targeted Theranostic Nanoparticles for Brain Tumor Treatment.
Pharmaceutics. 2018 Oct 9;10(4):181. doi: 10.3390/pharmaceutics10040181.
9
Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients.
J Thorac Dis. 2018 Aug;10(8):4682-4685. doi: 10.21037/jtd.2018.07.66.
本文引用的文献
1
A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.
Oncotarget. 2017 Sep 5;8(62):104928-104945. doi: 10.18632/oncotarget.20650. eCollection 2017 Dec 1.
2
Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.
Ther Deliv. 2017 Nov;8(11):1003-1018. doi: 10.4155/tde-2017-0062.
3
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017.
4
Design, synthesis and antiproliferative activity of decarbonyl luotonin analogues.
Eur J Med Chem. 2017 Sep 29;138:932-941. doi: 10.1016/j.ejmech.2017.07.027. Epub 2017 Jul 18.
5
Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy.
Int J Pharm. 2017 Aug 30;529(1-2):506-522. doi: 10.1016/j.ijpharm.2017.07.018. Epub 2017 Jul 12.
6
Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers.
Colloids Surf B Biointerfaces. 2017 Sep 1;157:490-502. doi: 10.1016/j.colsurfb.2017.06.025. Epub 2017 Jun 21.
7
A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF).
Nat Chem. 2017 Jul;9(7):715-722. doi: 10.1038/nchem.2749. Epub 2017 Mar 27.
8
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.
Mol Cell Biochem. 2017 Dec;436(1-2):119-136. doi: 10.1007/s11010-017-3084-z. Epub 2017 Jun 5.
9
Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach.
Int J Pharm. 2017 Jun 30;526(1-2):506-515. doi: 10.1016/j.ijpharm.2017.04.078. Epub 2017 May 11.
10
Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells.
Sci Rep. 2017 Apr 21;7:46688. doi: 10.1038/srep46688.
Zotero 插件